☆ 4.3 Article

Pre-MASLD: Should it be defined separately?

Hepatobiliary & Pancreatic Diseases International (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

MAFLD: How is it different from NAFLD?

Cameron Gofton et al.

Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a term introduced in 2020 to describe fatty liver disease associated with systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria for easy diagnosis, and it has shown superiority in various aspects compared to NAFLD, including liver and extrahepatic mortality, disease associations, and identification of high-risk individuals. MAFLD has been adopted by many national and international societies due to its concise diagnostic criterion, removal of exclusionary criteria, and reduction in stigmatization. This article explores the differences between MAFLD and NAFLD diagnosis, benefits, limitations, and the impact of MAFLD terminology on research.

CLINICAL AND MOLECULAR HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study

Jiarong Xie et al.

Summary: This study aimed to develop a simplified set of metabolic syndrome-based criteria for identifying MAFLD and predicting MAFLD-related metabolic diseases. Participants who met the simplified criteria had a higher risk of incident T2DM and hypertension compared to those who met the original criteria.

HEPATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD

Arka De et al.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of mortality outcomes in individuals with MASLD and/or MAFLD

Qianwen Zhao et al.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study

Jing Zeng et al.

Hepatobiliary & Pancreatic Diseases International (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults

Jiarong Xie et al.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?

Yasser Fouad et al.

Summary: There is a polarizing debate in hepatology regarding the name and redefinition of fatty liver disease associated with metabolic dysfunction. While there is growing evidence supporting the use of the term metabolic (dysfunction) associated fatty liver disease (MAFLD) for clinical and academic practice, controversy remains. This opinion piece argues that understanding scientific consensus and exploring alternative models for reaching agreement are crucial in this field.

LIVER INTERNATIONAL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Asian perspective on NAFLD-associated HCC

Terry Cheuk-Fung Yip et al.

Summary: Recent data shows that non-alcoholic fatty liver disease (NAFLD) has become a significant public health issue in Asia, with a population prevalence of 34%. The rising trend of NAFLD also leads to an increase in NAFLD-associated hepatocellular carcinoma (HCC). This review focuses on the changing epidemiology of HCC in Asia over the past 30 years, highlighting the importance of traditional risk factors and specific genetic polymorphism in East Asia. Additionally, non-obese individuals with NAFLD are commonly observed in Asia.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

Kiarash Riazi et al.

Summary: The prevalence and incidence of non-alcoholic fatty liver disease (NAFLD) are significantly increasing worldwide, with higher rates in men compared to women. Greater awareness and cost-effective risk stratification strategies are needed to address the growing burden of NAFLD.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Zobair M. Younossi et al.

Summary: The article discusses the proposal to rename NAFLD to MAFLD, highlighting the shortcomings of the new term and warning that changing the name without a comprehensive understanding may have negative implications for the field. The recommendation is to establish a true international consensus group to assess the impact and consequences of the terminology change and make recommendations based on available evidence to move the field forward.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Redefining fatty liver disease: an international patient perspective

Gamal Shiha et al.

Summary: The article discusses the renaming of non-alcoholic fatty liver disease to metabolic-associated fatty liver disease, with patient advocacy groups enthusiastically supporting this change. They believe it will have a positive impact on patient care, quality of life, and reduce burdens on healthcare systems.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease

Shang-Chin Huang et al.

Summary: The study examined and compared the clinical and histologic features of MAFLD versus NAFLD in patients with biopsy-proven hepatic steatosis. Results showed that MAFLD patients exhibited a higher degree of disease severity, and advanced fibrosis was associated with hepatitis B virus infection and metabolic diseases.

GUT AND LIVER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD

Vy H. Nguyen et al.

Summary: The study found that individuals meeting the criteria for MAFLD had more comorbidities and worse prognosis compared to those with NAFLD only. Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality, followed by NAFLD-MAFLD and non-MAFLD NAFLD participants. The MAFLD criteria should be considered in the general population to identify high-risk groups for early interventions.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population

Stefano Ciardullo et al.

Summary: Limited data are available on the epidemiological implications of renaming NAFLD to MAFLD. A cross-sectional study using NHANES data found similar prevalence rates of NAFLD and MAFLD in the general US population, with a high agreement between the two definitions and higher rates among Hispanic individuals. Additionally, patients with either NAFLD or MAFLD showed similar risk of advanced liver fibrosis.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Endocrinology & Metabolism

MAFLD and risk of CKD

Dan-Qin Sun et al.

Summary: This study showed that patients with MAFLD have a higher risk of CKD compared to NAFLD patients, and the severity of MAFLD is associated with CKD and abnormal albuminuria.

METABOLISM-CLINICAL AND EXPERIMENTAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

Stephen A. Harrison et al.

Summary: In a cohort of asymptomatic middle-aged Americans, the prevalence of NAFLD was 38%, NASH was 14%, and significant liver fibrosis was present in 6% of the participants.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Giovanni Targher et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) have a complex relationship with each other, influencing the risk of adverse clinical outcomes. The severity of NAFLD is directly related to the risk of developing T2DM, while improvement of NAFLD may lower the risk of T2DM.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Giovanni Targher et al.

Summary: NAFLD is not only a global public health issue but also proven to be a systemic disease, closely related to various extrahepatic complications. Addressing NAFLD requires establishing a multidisciplinary working group and framework to achieve comprehensive, person-centered care and management.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach

Tsubasa Tsutsumi et al.

Summary: The study found that MAFLD patients had a higher risk of worsening ASCVD compared to NAFLD patients. The superiority of MAFLD was attributed to metabolic dysfunction rather than moderate alcohol consumption.

HEPATOLOGY RESEARCH (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States

Donghee Kim et al.

Summary: This study demonstrated that metabolic dysfunction-associated fatty liver disease (MAFLD) was associated with an increased risk of all-cause mortality in US adults, while non-alcoholic fatty liver disease (NAFLD) showed no association with all-cause mortality after adjusting for metabolic risk factors. Individuals who met the criteria for MAFLD but not NAFLD had a higher risk of all-cause mortality.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis

Jiaofeng Huang et al.

Summary: The study found that the MAFLD criteria may overlook some fatty liver patients without metabolic risks, who may also have steatohepatitis and significant fibrosis.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications

Giovanni Targher et al.

GUT (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Mohammed Eslam et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of MAFLD and NAFLD diagnostic criteria in real world

Su Lin et al.

LIVER INTERNATIONAL (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

History of Nonalcoholic Fatty Liver Disease

Amedeo Lonardo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

MAFLD identifies patients with significant hepatic fibrosis better than NAFLD

Sakura Yamamura et al.

LIVER INTERNATIONAL (2020)

添加到收藏夹

Letter Gastroenterology & Hepatology

MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?

Jiaofeng Huang et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Zobair M. Younossi et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study

Haesuk Park et al.

JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Parambir S. Dulai et al.

HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism

Xingyong Wan et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Cell Biology

A comprehensive definition for metabolic syndrome

Paul L. Huang

DISEASE MODELS & MECHANISMS (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.